Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Expert Review of Clinical Pharmacology|December 23, 2017
The pharmacological treatment of bronchiectasisAndrea S Melani, Nicola Lanzarone, Paola RottoliLife Sciences|June 24, 2020
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitisMiriana d'Alessandro, Laura Bergantini, Paolo Cameli, et al.European Journal of Clinical Investigation|April 21, 2020
Serum KL-6 levels in pulmonary Langerhans' cell histiocytosisMiriana d'Alessandro, Laura Bergantini, Paolo Cameli, et al.Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia|July 30, 2020
Lung transplant in patients with familial pulmonary fibrosisDavid Bennett, Antonella Fossi, Nicola Lanzarone, et al.Internal Medicine Journal|February 11, 2020
Antithrombin III as predictive indicator of survival in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib: a preliminary studyLaura Bergantini, Miriana d'Alessandro, Paolo Cameli, et al.Clinical and Experimental Medicine|January 24, 2020
BAL biomarkers' panel for differential diagnosis of interstitial lung diseasesMiriana d'Alessandro, Alfonso Carleo, Paolo Cameli, et al.Clinical and Experimental Medicine|February 10, 2020
Correction to: BAL biomarkers' panel for differential diagnosis of interstitial lung diseasesMiriana d'Alessandro, Alfonso Carleo, Paolo Cameli, et al.Interactive Cardiovascular and Thoracic Surgery|January 17, 2019
Postoperative acute kidney injury in lung transplant recipientsDavid Bennett, Antonella Fossi, Luca Marchetti, et al.Panminerva Medica|March 21, 2020
Pirfenidone in chronic lung allograft dysfunction: a single cohort studyDavid Bennett, Nicola Lanzarone, Antonella Fossi, et al.Scientific Reports|July 27, 2025
Circulating biomarkers in patients with progressive fibrosing interstitial lung disease treated with nintedanib: a pilot studyVitale Miceli, Adriana Callari, Elisa Calzolari, et al.Pageof 2